(VIR) – Reuters
-
Vir Biotech gets U.S. funding for flu-prevention antibody
-
GSK, Vir ramping up U.S. output of COVID antibody drug
-
U.S. secures 600,000 more doses of GSK-Vir's COVID-19 therapy
-
GSK says tests indicate antibody drug works against Omicron
-
U.S. secures GSK-Vir COVID-19 antibody therapy doses worth $1 billion
-
GSK-Vir COVID-19 antibody works as shot in the arm as well as infusion
Back to VIR Stock Lookup